| Gao, Feng |
NCT04683406: A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A |
|
|
| Completed | 3 | 750 | RoW | ZSP1273 600 mg, Placebo to Oseltamivir, Oseltamivir(oral), Placebo to ZSP1273 | Guangdong Raynovent Biotech Co., Ltd | Influenza A | 04/23 | 05/23 | | |
| Recruiting | 3 | 2100 | Europe, Canada, Japan, US, RoW | Rimegepant/BHV3000, Matching placebo | Pfizer | Pediatric Migraine | 01/29 | 01/29 | | |
| Recruiting | 2/3 | 104 | RoW | B007, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Generalized Myasthenia Gravis | 06/26 | 06/26 | | |
NCT06413654: A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) |
|
|
| Recruiting | 2/3 | 132 | RoW | B001, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Neuromyelitis Optica Spectrum Disorders | 10/27 | 02/29 | | |
NCT04543279: Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia |
|
|
| Terminated | 2 | 3 | US | Fostamatinib, Tavalisse, Ruxolitinib, Jakafi | Washington University School of Medicine, Rigel Pharmaceuticals | Myelofibrosis, Thrombocytopenia | 07/22 | 07/22 | | |
NCT06483100: Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance |
|
|
| Recruiting | 2 | 65 | US | Elrantamab, clonoSEQ | Washington University School of Medicine, National Comprehensive Cancer Network, Pfizer, Rapid Novor | Multiple Myeloma | 12/31 | 12/31 | | |
NCT06445166: Propranolol for the Treatment of Kaposi Sarcoma in Adults |
|
|
| Not yet recruiting | 2 | 25 | US | Propranolol Hydrochloride | Washington University School of Medicine | Kaposi Sarcoma | 06/27 | 12/27 | | |
CNS-PHLAT, NCT06687772: CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma with Thiotepa-based Autologous Stem Cell Transplant |
|
|
| Not yet recruiting | 2 | 36 | US | Thiotepa, Carmustine, Autologous Stem Cell Transplant, ASCT, Anthracycline-based induction chemotherapy | Washington University School of Medicine | Diffuse Large B Cell Lymphoma | 08/27 | 08/29 | | |
NCT06044350: A Clinical Trial of BAT4406F Injection in Patients with Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 2 | 162 | RoW | BAT4406F Injection, BAT4406F Placebos | Bio-Thera Solutions | Optic Neuromyelitis Spectrum Disease | 05/25 | 05/26 | | |
NCT04354025: Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML |
|
|
| Withdrawn | 2 | 48 | NA | Cytokine induced memory-like NK cells, CIML NK cells, Fludarabine, Ara-C, Cytarabine, G-CSF, Filgrastim, Interleukin-2, IL-2, Leukapheresis | Washington University School of Medicine | Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | 09/26 | 07/28 | | |
NCT05820763: Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant |
|
|
| Withdrawn | 2 | 35 | NA | Selinexor, EXPOVIO, KPT-330, Lenalidomide, Revlimid, Dexamethasone, Decadron | Washington University School of Medicine, Karyopharm Therapeutics Inc | Multiple Myeloma, Myeloma-Associated Amyloidosis | 01/27 | 01/27 | | |
NCT05483010: Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS) |
|
|
| Recruiting | 2 | 16 | US | Atorvastatin, Lipitor, Rosuvastatin, Crestor | Washington University School of Medicine | Clonal Cytopenia of Undetermined Significance, Myelodysplastic Syndromes | 05/27 | 05/27 | | |
NCT02756962: Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance |
|
|
| Active, not recruiting | 2 | 107 | US | Cytarabine, Ara-C, Cytosar-U, Tarabine-PFS, AraC, Allogeneic stem cell transplant, AlloSCT, Bone marrow aspiration, Punch skin biopsy, ClinSeq | Washington University School of Medicine, The Leukemia and Lymphoma Society, American Society of Hematology | Acute Myeloid Leukemia | 07/29 | 07/29 | | |
ABCD-NK, NCT06158828: Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRĪ±Ī² T Cell Depleted Haploidentical Transplant in AML |
|
|
| Recruiting | 1/2 | 48 | US | Rabbit Anti thymocyte globulin, rATG, Busulfan, Fludarabine, Thiotepa, Melphalan, Evolema, Alkeran, TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft, TCRab/CD19+ depleted haploidentical HPC graft, memory-like natural killer cells, ML NK cells, IL-2, Plerixafor, Granulocyte Colony-Stimulating Factor, G-CSF, CliniMACS | Washington University School of Medicine, The Leukemia and Lymphoma Society, Rising Tide Foundation, St. Louis Children's Hospital Foundation | AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric, Acute Myeloid Leukemia | 09/28 | 05/30 | | |
PRiME II, NCT06639607: PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma |
|
|
| Not yet recruiting | 1/2 | 68 | US | PEP-CMV vaccine, Tetanus booster, Td booster, Nivolumab, Temozolomide | Washington University School of Medicine, National Cancer Institute (NCI) | Diffuse Midline Glioma, Diffuse Midline High-grade Glioma, Medulloblastoma, Ependymoma | 07/30 | 05/42 | | |
NCT04077866: B7-H3 CAR-T for Recurrent or Refractory Glioblastoma |
|
|
| Recruiting | 1/2 | 40 | RoW | Temozolomide, TMZ, B7-H3 CAR-T | Second Affiliated Hospital, School of Medicine, Zhejiang University, Ningbo Yinzhou People's Hospital, Huizhou Municipal Central Hospital, BoYuan RunSheng Pharma (Hangzhou) Co., Ltd. | Recurrent Glioblastoma, Refractory Glioblastoma | 06/25 | 08/25 | | |
NCT06185751: Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma |
|
|
| Recruiting | 1 | 25 | US | WS-CART-CS1, Lymphodepleting chemotherapy | Washington University School of Medicine, Paula C. & Rodger O. Riney Blood Cancer Research | Multiple Myeloma | 08/29 | 08/40 | | |
NCT06623630: Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function |
|
|
| Recruiting | 1 | 12 | US | Cyclophosphamide, Ciltacabtagene Autoleucel, Carvykti, cilta-cel, Total body irradiation, TBI | Washington University School of Medicine, American Cancer Society, Inc., Cures Within Reach | Multiple Myeloma | 04/26 | 03/27 | | |
NCT05743595: Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma |
|
|
| Recruiting | 1 | 12 | US | Personalized Neoantigen DNA vaccine, Retifanlimab, INCMGA00012, MGA012, TDS-IM v 2.0 electroporation device | Washington University School of Medicine, Incyte Corporation, PapiVax Biotech, Inc., The Foundation for Barnes-Jewish Hospital | Unmethylated Glioblastoma | 01/26 | 10/28 | | |
NCT06523699: Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant |
|
|
| Not yet recruiting | 1 | 30 | US | Recombinant glycosylated human interleukin-7, CYT107, r-hIL-7, Melphalan, Autologous hematopoietic cell transplant, AHCT | Washington University School of Medicine, Revimmune | Multiple Myeloma | 01/29 | 01/29 | | |
NCT06529822: Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease |
|
|
| Not yet recruiting | 1 | 16 | US | Synthetic long peptide personalized cancer vaccine, PCV, Poly ICLC, Hiltonol, Signatera assay | Washington University School of Medicine, Natera, Inc. | Muscle-Invasive Bladder Carcinoma | 09/28 | 08/33 | | |
NCT05044039: Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy |
|
|
| Recruiting | 1 | 43 | US | Duvelisib | Washington University School of Medicine, SecuraBio, The Foundation for Barnes-Jewish Hospital, National Cancer Institute (NCI) | Non-hodgkin Lymphoma, Acute Lymphocytic Leukemia | 12/25 | 05/30 | | |
NCT05412290: Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma |
|
|
| Recruiting | 1 | 15 | US | Mosunetuzumab, RO7030816, BTCT4465A | Washington University School of Medicine, Genentech, Inc. | B Cell Lymphoma, Aggressive Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma, Follicular Lymphoma Grade 3 | 07/27 | 06/29 | | |
NCT05111353: Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery |
|
|
| Recruiting | 1 | 34 | US | Optimized neoantigen synthetic long peptide vaccine, Poly-ICLC, Hiltonol | Washington University School of Medicine, National Cancer Institute (NCI), Leidos, UNICO Foundation | Pancreas Cancer, Pancreatic Cancer, Cancer of the Pancreas | 12/25 | 12/27 | | |
NCT06008808: Ruxolitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation |
|
|
| Recruiting | 1 | 49 | US | Ruxolitinib, Jakafi | Washington University School of Medicine, Incyte Corporation | Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease | 09/26 | 12/26 | | |
NCT05377827: Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies |
|
|
| Recruiting | 1 | 54 | US | WU-CART-007 | Washington University School of Medicine, Wugen, Inc. | T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma, Adult T Cell Leukemia, Adult T Cell Lymphoma, T Cell Prolymphocytic Leukemia, Extranodal NK/T-cell Lymphoma, Transformed Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma | 04/26 | 04/26 | | |
NCT05187182: CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer |
|
|
| Recruiting | 1 | 42 | US | CA-4948, Nivolumab, Opdivo, Pembrolizumab, Keytruda, Trastuzumab, Herceptin, mFOLFOX7 | Washington University School of Medicine, Curis, Inc., The Foundation for Barnes-Jewish Hospital | Gastric Cancer, Esophageal Cancer, Stomach Cancer, Esophagus Cancer, Gastroesophageal Junction Cancer | 09/27 | 06/28 | | |
NCT05011422: Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies |
|
|
| Recruiting | 1 | 32 | US | Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus | Washington University School of Medicine | Pediatric Hematologic Malignancies | 11/27 | 11/27 | | |
NCT05629546: Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors |
|
|
| Recruiting | 1 | 33 | US | Cytokine-induced memory-like natural killer cells, ML NK cells, CIML, Relatilmab, Opdualag, Nivolumab | Washington University School of Medicine, Melanoma Research Alliance, Rising Tide Foundation | Advanced Melanoma, Metastatic Melanoma | 02/29 | 11/30 | | |
| Recruiting | N/A | 25000 | RoW | | Second Affiliated Hospital, School of Medicine, Zhejiang University, The People's Hospital of Haiyan, Taizhou First People's Hospital, The First People's Hospital of Pinghu, The 2nd People's Hospital of Quzhou | Stroke, Intracerebral Hemorrhage | 12/30 | 12/33 | | |
NCT05472025: Clinical Study of Combined Carotid Artery With Inferior Vena Cava Ultrasonography to Predict Hypotension After Induction of General Anesthesia |
|
|
| Recruiting | N/A | 106 | RoW | | Tongji Hospital | Ultrasound Guidance | 04/23 | 04/23 | | |
ANGEL-REBOOT, NCT05122286: Randomized Study of Bailout Intracranial Angioplasty Following Thrombectomy for Acute Large Vessel Occlusion |
|
|
| Completed | N/A | 348 | RoW | Bailout angioplasty, Standard therapy | Beijing Tiantan Hospital | Acute Ischemic Stroke | 06/23 | 08/23 | | |
NCT04614987: Serum Neurofilament Light (NfL) as a Marker for Brain Injury in Individuals Undergoing Chimeric Antigen Receptor-modified T Therapy |
|
|
| Terminated | N/A | 17 | US | | Washington University School of Medicine, McDonnell Center, Paula and Roger Riney Blood Cancer Research | Neurotoxicity | 09/23 | 09/23 | | |
NCT05556889: Safety and Analgesic Efficacy of a Modified Auriculotemporal Nerve Block |
|
|
| Recruiting | N/A | 252 | RoW | a modified auriculotemporal nerve blockade, Traditional auriculotemporal nerve blockade | Tongji Hospital | Safety and Efficacy, Scalp Nerve Block | 12/24 | 12/24 | | |
| Completed | N/A | 336 | RoW | Esketamine, Es group, Normal saline, Ns group | Ailin Luo, Maternal and Child Health Hospital of Hubei Province, Jingmen No.1 People's Hospital | Esketamine, Postpartum Depression | 03/24 | 03/24 | | |
NCT05972252: First-in-man Study of the Cerebrovascular Interventional Procedural Control System |
|
|
| Recruiting | N/A | 10 | RoW | Cerebrovascular Interventional Procedural Control System | Hangzhou Dinova Neuroscience Technology Co., Ltd | Acute Ischemic Stroke | 12/23 | 03/24 | | |
CSILS, NCT04527861: Oncologic Outcomes of Single-incision Versus Conventional Laparoscopic Surgery for Colorectal Cancer |
|
|
| Recruiting | N/A | 710 | RoW | Single-incision Laparoscopic Surgery, SILS, Conventional Laparoscopic Surgery, CLS | Ruijin Hospital, Dongfang Hospital Affiliated to Tongji University, Fudan University, Changhai Hospital, Shengjing Hospital, RenJi Hospital, Liaoning Cancer Hospital & Institute, Zhejiang Provincial People's Hospital, Shandong Provincial Hospital, The General Hospital of Western Theater Command, Shanghai Jiao Tong University School of Medicine | Colorectal Cancer, Colon Cancer, Rectal Cancer | 04/24 | 04/29 | | |
NCT04703712: Lens Extraction Combined With Goniosynechialysis Versus Trabeculectomy |
|
|
| Recruiting | N/A | 316 | RoW | Lens extraction combined with goniosynechialysis, Trabeculectomy surgery | Eye & ENT Hospital of Fudan University | Glaucoma, Angle-Closure | 12/24 | 12/24 | | |
NCT05352074: STOPS Trial: Total vs Subtotal Colectomy for Slow Transit Constipation |
|
|
| Recruiting | N/A | 202 | RoW | subtotal colectomy with cecal-rectal anastomosis, total colectomy with ileorectal anastomosis | Third Military Medical University | Slow Transit Constipation, Surgery | 12/24 | 12/26 | | |
| Not yet recruiting | N/A | 20 | US | SkinScan3D camera, SS3D | Washington University School of Medicine, National Cancer Institute (NCI), Pensievision | Kaposi Sarcoma | 04/26 | 04/26 | | |
NCT05582551: Patients At Risk for Sensory Screening (HPARSS) to Enhance Sensory Deficit Screening in Childhood Cancer Survivors |
|
|
| Recruiting | N/A | 146 | US | Highlighting Patients at Risk for Sensory Screening (HPARSS) | Washington University School of Medicine, St. Jude Children's Research Hospital | Childhood Cancer | 05/25 | 05/25 | | |
ANGEL-BAO, NCT06101667: Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window |
|
|
| Recruiting | N/A | 224 | RoW | Best medical management, Endovascular treatment | Beijing Tiantan Hospital | Acute Ischemic Stroke, Basilar Artery Occlusion | 09/25 | 12/25 | | |
| Recruiting | N/A | 856 | RoW | | Second Affiliated Hospital, School of Medicine, Zhejiang University | Intracerebral Hemorrhage | 12/25 | 12/26 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasĆ¢āĀ¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
NCT05864976: Neurosurgical Neuronavigation Using Resting State MRI and Machine Learning |
|
|
| Recruiting | N/A | 100 | US | Support Vector Machine | Washington University School of Medicine, National Cancer Institute (NCI) | Glioblastoma Multiforme | 01/30 | 01/30 | | |
| Recruiting | N/A | 10000 | RoW | | Second Affiliated Hospital, School of Medicine, Zhejiang University | Intracerebral Hemorrhage | 10/21 | 10/25 | | |
CATCH, NCT05502874: Multicenter Registry for Assessment of Markers of Early Neurological Deterioration in Primary Intracerebral Hemorrhage |
|
|
| Not yet recruiting | N/A | 1600 | RoW | | Second Affiliated Hospital, School of Medicine, Zhejiang University | Intracerebral Hemorrhage, Neurologic Deficits, Hemorrhagic Stroke, Hemorrhage | 12/24 | 10/25 | | |
| Liu, Jian Xiong |
| Not yet recruiting | 4 | 314 | RoW | Eldecalcitol capsules, Edirol, Alfacalcidol tablets, Calcium carbonate tablets | Chinese SLE Treatment And Research Group, Beijing Life oasis public service center | Rheumatoid Arthritis, Osteoporosis, Osteopenia | 12/25 | 03/26 | | |
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer |
|
|
| Active, not recruiting | 3 | 274 | RoW | BPI-16350, placebo, Fulvestrant | Betta Pharmaceuticals Co., Ltd. | Breast Cancer | 12/23 | 07/25 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases |
|
|
| Active, not recruiting | 2/3 | 301 | RoW | RC48-ADC, RC48, Lapatinib, Capecitabine | RemeGen Co., Ltd. | Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases | 07/24 | 12/24 | | |
NCT05744687: Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer |
|
|
| Recruiting | 2/3 | 374 | RoW | SPH4336 Tablets 400mg, SPH4336 Tablets Placebo | Shanghai Pharmaceuticals Holding Co., Ltd | Locally Advanced or Metastatic Breast Cancer | 05/25 | 05/25 | | |
NCT05621434: A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer |
|
|
| Not yet recruiting | 2 | 63 | NA | Inetetamab, pyrotinib, chemotherapy, Inetetamab for injection, Pyrotinib maleate | Fujian Medical University | HER2-positive Recurrent/Metastatic Breast Cancer | 12/24 | 12/25 | | |
NCT04778839: Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors. |
|
|
| Recruiting | 1 | 98 | RoW | Paclitaxel Micelles for Injection, Paclitaxel injection | First Affiliated Hospital of Zhejiang University, Hangzhou Dihua Biotechnology Co., LTD. | Advanced Solid Tumors | 10/24 | 12/24 | | |
NCT04861779: A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies |
|
|
| Recruiting | 1 | 156 | RoW | HSK29116 | Haisco Pharmaceutical Group Co., Ltd. | Relapsed/Refractory B-Cell Malignancies | 08/23 | 10/23 | | |
NCT06462326: A Study to Compare the Effect of Omadacycline Versus Moxifloxacin in Healthy Adult Volunteers |
|
|
| Completed | 1 | 24 | RoW | Moxifloxacin Oral Tablet, Avelox, Omadacycline Oral Tablet, NUZYRA | Zai Lab (Hong Kong), Ltd. | Healthy Volunteer | 09/24 | 09/24 | | |
KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 |
|
|
| Recruiting | 1 | 162 | RoW | CMG901 | Keymed Biosciences Co.Ltd | Advanced Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Pancreatic Cancer | 05/24 | 10/24 | | |
| Recruiting | 1 | 54 | RoW | HF1K16 /Arm 45 mg/mĀ², HF1K16 /Arm 90 mg/mĀ², HF1K16 /Arm 120 mg/mĀ², HF1K16 /Arm 160 mg/mĀ², HF1K16 /Arm 120 mg or 180 mg | HighField Biopharmaceuticals Corporation, Tigermed Consulting Co., Ltd | Solid Tumor, Adult | 04/25 | 11/25 | | |
NCT04187469: Efficacy and Safety of Isoniazid, Rifampicin and Moxifloxacin for the Intensive Phase of Initial Therapy of PTB |
|
|
| Not yet recruiting | N/A | 286 | RoW | Moxifloxacin, Isoniazid, Rifampicin, Avelox, Myambutol, Nydrazid, Rifampin, Rifadin, Rifampicin,Isoniazid,Pyrazinamide,Ethambutol, Myambutol,Nydrazid,Rifampin,Rifadin | Fifth Affiliated Hospital, Sun Yat-Sen University | Pulmonary Tuberculosis | 02/23 | 02/24 | | |
IBBR, NCT03589924: Study to Compare the Safety of Immediate One-stage With Expander-Implant Two-stage Augmented With TiLoopĀ® Bra(COSTA) |
|
|
| Active, not recruiting | N/A | 440 | RoW | Immediate IBBR+TiLoopĀ®Bra, Immediate-delayed IBBR+TiLoopĀ®Bra | Jiong Wu, First Hospital of China Medical University, Second Affiliated Hospital, School of Medicine, Zhejiang University, The First Affiliated Hospital with Nanjing Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Cancer | 04/23 | 09/24 | | |
MAGIC-MT, NCT04700345: Managing Non-acute Subdural Hematoma Using Liquid Materialsļ¼a Chinese Randomized Trial of MMA Treatment |
|
|
| Active, not recruiting | N/A | 722 | RoW | Onyx, Burr-hole, Medical Management | Huashan Hospital, Shanghai Municipal Health Commission, Shanghai Shen Kang Hospital Development Center | Subdural Hematoma, Non-acute | 08/23 | 06/24 | | |
| Recruiting | N/A | 2132 | RoW | caFFR, Coronary Angiography-Derived Fractional Flow Reserve, FFR, Fractional Flow Reserve | Peking University First Hospital, Rainmed Ltd., Suzhou, China | Coronary Artery Disease, Coronary Stenosis, Myocardial Ischaemia, Coronary Circulation, Stable Angina Pectoris, Unstable Angina Pectoris, Asymptomatic Ischemia, Acute Myocardial Infarction, Percutaneous Coronary Intervention | 12/23 | 12/25 | | |
| Not yet recruiting | N/A | 32 | RoW | ATRA, Toripalimab | First Affiliated Hospital of Zhejiang University, Shanghai Longfine Biotechnology Co., Ltd., TopAlliance | Triple-negative Breast Cancer | 04/26 | 04/26 | | |
NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus |
|
|
| Recruiting | N/A | 184 | RoW | Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter | Shanghai Bluesail Boyuan Medical Technology Co., Ltd. | Coronary Artery Disease, Intravascular Lithotripsy | 12/24 | 09/25 | | |
NCT05760157: Mulltimodal Dynamic Risk Assessment Systems of Heart Failure in Patients With Myocardial Infarction. |
|
|
| Recruiting | N/A | 567 | RoW | Possible risk factors of heart failure | Jian Liu, Peking University Third Hospital, Beijing Anzhen Hospital, Navy General Hospital, Beijing, Beijing Luhe Hospital, Beijing Chao Yang Hospital | Heart Failure, Acute Myocardial Infarction | 12/25 | 12/25 | | |
| wen, liang zi |
NCT03732547: Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 60 | RoW | PD-1 mAb, Programmed cell death-1 monoclonal antibody, PolyIC, Polyinosinic-polycytidylic acid | Second Affiliated Hospital, School of Medicine, Zhejiang University | Carcinoma, Hepatocellular | 10/21 | 10/23 | | |
| Liang, Tingbo |
NCT04300114: A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy |
|
|
| Terminated | 3 | 5 | RoW | Fluzoparib, SHR3162, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Pancreatic Cancer | 02/22 | 02/22 | | |
NCT03750669: Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer |
|
|
| Active, not recruiting | 3 | 324 | RoW | AG regimen, Nab-paclitaxel and Gemcitabine, mFolfirinox, Folic acid, 5- fluorouracil, irinotecan and oxaliplatin | Second Affiliated Hospital, School of Medicine, Zhejiang University | Pancreatic Adenocarcinoma Resectable, Neoadjuvant Chemotherapy | 04/24 | 04/26 | | |
NCT03732547: Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 60 | RoW | PD-1 mAb, Programmed cell death-1 monoclonal antibody, PolyIC, Polyinosinic-polycytidylic acid | Second Affiliated Hospital, School of Medicine, Zhejiang University | Carcinoma, Hepatocellular | 10/21 | 10/23 | | |
NCT06746480: Clinical Study of VG161 in Advanced Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 33 | RoW | Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), VG161 | CNBG-Virogin Biotech (Shanghai) Ltd. | Advanced Intrahepatic Cholangiocarcinoma | 09/25 | 12/25 | | |
AK104-209, NCT04728321: A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma |
|
|
| Completed | 2 | 32 | RoW | AK104 lenvatinib, AK104 | Akeso, Akeso Pharmaceuticals, Inc. | Hepatocellular Carcinoma | 08/22 | 08/23 | | |
CISLD-12, NCT05213221: Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients |
|
|
| Completed | 2 | 39 | RoW | Envafolimab, TACE, Lenvatinib | Zhejiang University | Advanced Hepatocellular Carcinoma | 09/22 | 06/23 | | |
NCT03662412: Study of Sirolimus in Patients With Advanced Pancreatic Cancer |
|
|
| Recruiting | 2 | 36 | RoW | Sirolimus, Rapamycin | Second Affiliated Hospital, School of Medicine, Zhejiang University | Pancreatic Cancer | 06/23 | 06/23 | | |
NCT05451290: Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer |
|
|
| Not yet recruiting | 2 | 30 | RoW | Camrelizumab, apatinib, gemcitabine, oxaliplatin, tegafur, surgery | First Affiliated Hospital of Zhejiang University | Advanced Biliary Tract Carcinoma | 08/23 | 09/25 | | |
NCT05312216: Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2 | 25 | RoW | Durvalumab plus Lenvatinib | Zhejiang University | Hepatocellular Carcinoma | 03/24 | 06/24 | | |
NCT04930315: SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 78 | RoW | Apatinib Mesylate, Camrelizumab | Zhejiang University | Hepatocellular Carcinoma | 06/24 | 06/24 | | |
NCT06465563: Adebrelimab With or Without SHR-8068 in Combination With Cisplatin Plus Gemcitabine as First-line Treatment in Patients With Advanced Biliary Tract Cancer |
|
|
| Recruiting | 2 | 80 | RoW | SHR-8068, Adebrelimab, Cisplatin, Gemcitabine | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Biliary Tract Cancer | 12/26 | 12/26 | | |
NCT05678270: A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 70 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Intrahepatic Cholangiocarcinoma (ICC) | 05/26 | 12/26 | | |
ATTR-CM, NCT06539208: A Phase I/IIaļ¼Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy |
|
|
| Recruiting | 1/2 | 31 | RoW | YOLT-201 | YolTech Therapeutics Co., Ltd | Transthyretin Amyloidosis Polyneuropathy, Transthyrexin Amyloidosis Cardiomyopathy | 06/25 | 06/26 | | |
| Recruiting | 1/2 | 63 | RoW | Bortezomib Injection, Sintilimab, mFOLFIRINOX | Zhejiang University | Pancreas Cancer | 09/26 | 03/28 | | |
NCT05162118: Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer |
|
|
| Recruiting | 1/2 | 51 | RoW | Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) in combination with Nivolumab, VG161 + Nivolumab | Zhejiang University | Advanced Pancreatic Cancer | 03/25 | 12/25 | | |
NCT04635527: A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma |
|
|
| Terminated | 1 | 10 | RoW | IBI318, cTACE, placebo | Innovent Biologics (Suzhou) Co. Ltd. | Hepatocellular Carcinoma | 08/21 | 03/23 | | |
SecPac02, NCT03716596: SBRT and Anti-programmed Cell Death Protein 1(Anti-PD-1) in Late Stage or Recurrent Pancreatic Cancer Patients |
|
|
| Terminated | 1 | 8 | RoW | SBRT, Stereotactic Body Radiotherapy, anti-PD-1 antibody, keytruda | Second Affiliated Hospital, School of Medicine, Zhejiang University | Pancreatic Cancer | 10/19 | 10/19 | | |
NCT04806464: Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer |
|
|
| Recruiting | 1 | 44 | RoW | Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), VG161 | CNBG-Virogin Biotech (Shanghai) Ltd. | Primary Liver Cancer | 03/22 | 12/24 | | |
NCT06310590: Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 40 | RoW | NRT6003 Injection, Yttrium-90 carbon microspheres | Chengdu New Radiomedicine Technology Co. LTD. | Unresectable Hepatocellular Carcinoma | 10/25 | 10/25 | | |
NCT05100251: Clinical Trial of WBC100 on Advanced Solid Tumor |
|
|
| Recruiting | 1 | 90 | RoW | WBC100 QOD, WBC100 QD, WBC100 BID | Zhejiang University | Solid Tumor | 10/25 | 10/25 | | |
CIBI363A102, NCT05460767: Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma |
|
|
| Recruiting | 1 | 260 | RoW | IBI363 | Innovent Biologics (Suzhou) Co. Ltd. | Solid Tumors or Lymphoma | 03/24 | 12/24 | | |
VG201-C101, NCT05477849: A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients With Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection, VG2025 | Shanghai Virogin Biotech Co., Ltd. | Advanced Malignant Solid Tumor | 12/23 | 12/24 | | |
NCT05606380: A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Solid Tumors or Lymphoma |
|
|
| Active, not recruiting | 1 | 11 | RoW | HLX60 | Shanghai Henlius Biotech | Solid Tumor and Lymphoma | 08/24 | 02/25 | | |
NCT06478251: NW-301 TCR-T in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 1 | 9 | RoW | NW-301V, NW-301D | TingBo Liang, Neowise Biotechnology | Tumor, Solid | 06/26 | 06/27 | | |
NCT05155189: A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 44 | RoW | C-CAR031, Lenvatinib, PD-1(L1) monoclonal antibody | Zhejiang University | Hepatocellular Carcinoma | 05/26 | 05/41 | | |
| Recruiting | 1 | 21 | RoW | CT0180 Cells, CT0180 humanized anti GPC3 autogenous T Cell injection | Zhejiang University, CARsgen Therapeutics Co., Ltd. | Advanced Hepatocellular Carcinoma | 06/24 | 06/24 | | |
| Recruiting | 1 | 556 | RoW | IBI363 + chemotherapy, IBI363 + Investigator's Choice SOC | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Malignancies | 06/25 | 12/26 | | |
NCT06461624: Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 15 | RoW | anti-GPC3 CAR-T, CBG166 CAR-T | Zhejiang University, Carbiogene Therapeutics Co. Ltd. | Advanced Hepatocellular Carcinoma | 07/27 | 10/27 | | |
| Recruiting | 1 | 14 | RoW | YOLT-201 | Zhejiang University | Transthyroxin Amyloidosis Cardiomyopathy | 10/24 | 10/25 | | |
NCT06676982: Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 1 | 12 | RoW | anti-CD19 CAR-T | Zhejiang University, Juventas Cell Therapy Ltd. | Advanced Hepatocellular Carcinoma | 07/26 | 08/26 | | |
NCT06349408: IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 250 | RoW | IBI3001 | Innovent Biologics (Suzhou) Co. Ltd. | Locally Advanced Solid Tumor | 12/26 | 12/27 | | |
NCT06353672: A Study to Evaluate Safety and Feasibility of Robotic Liver Resection |
|
|
| Recruiting | N/A | 1000 | RoW | Robotic liver resection | Zhejiang University | Liver Diseases, Surgery | 12/25 | 12/26 | | |
